AU772156B2 - Compositions comprising GABA analogs and caffeine - Google Patents

Compositions comprising GABA analogs and caffeine Download PDF

Info

Publication number
AU772156B2
AU772156B2 AU46910/99A AU4691099A AU772156B2 AU 772156 B2 AU772156 B2 AU 772156B2 AU 46910/99 A AU46910/99 A AU 46910/99A AU 4691099 A AU4691099 A AU 4691099A AU 772156 B2 AU772156 B2 AU 772156B2
Authority
AU
Australia
Prior art keywords
caffeine
formula
gaba analog
mammal
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU46910/99A
Other languages
English (en)
Other versions
AU4691099A (en
Inventor
Leslie Magnus
Catherine A. Segal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU4691099A publication Critical patent/AU4691099A/en
Application granted granted Critical
Publication of AU772156B2 publication Critical patent/AU772156B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU46910/99A 1998-07-09 1999-06-18 Compositions comprising GABA analogs and caffeine Ceased AU772156B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9213198P 1998-07-09 1998-07-09
US60/092131 1998-07-09
PCT/US1999/013670 WO2000002562A1 (en) 1998-07-09 1999-06-18 Compositions comprising gaba analogs and caffeine

Publications (2)

Publication Number Publication Date
AU4691099A AU4691099A (en) 2000-02-01
AU772156B2 true AU772156B2 (en) 2004-04-08

Family

ID=22231777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46910/99A Ceased AU772156B2 (en) 1998-07-09 1999-06-18 Compositions comprising GABA analogs and caffeine

Country Status (13)

Country Link
US (1) US6326374B1 (enExample)
EP (1) EP1094817A1 (enExample)
JP (1) JP2002520286A (enExample)
KR (1) KR20010071777A (enExample)
AU (1) AU772156B2 (enExample)
BR (1) BR9911917A (enExample)
CA (1) CA2332915C (enExample)
ID (1) ID28277A (enExample)
NO (1) NO20010119D0 (enExample)
NZ (1) NZ508490A (enExample)
PL (1) PL345340A1 (enExample)
WO (1) WO2000002562A1 (enExample)
ZA (1) ZA200007168B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
AU4334900A (en) * 1999-04-09 2000-11-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1274306C (zh) 2001-09-03 2006-09-13 纽朗制药有限公司 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用
PT1727620E (pt) * 2004-03-12 2007-11-05 Warner Lambert Co Ligandos de biofosfina c1-simétricos e a sua utilização na síntese assimétrica da pregabalina
DE602005009161D1 (de) * 2004-04-01 2008-10-02 Warner Lambert Co Herstellung von p-chirogenen phospholanen und deren verwendung in der asymmetrischen synthese
CN1972904B (zh) * 2004-06-21 2011-02-02 沃尼尔·朗伯有限责任公司 普瑞巴林和相关化合物的制备
RS51411B (sr) * 2004-09-10 2011-02-28 Newron Pharmaceuticals S.P.A. Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
IN266803B (enExample) 2005-12-22 2015-06-03 Newron Pharm Spa
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CH699327B1 (de) 2007-02-14 2010-03-15 Oerlikon Heberlein Temco Wattw Vorrichtung zum gleichzeitigen Behandeln von mehreren multifilen Fäden.
EP2184986A4 (en) 2007-08-06 2010-12-15 Trinity Lab Inc PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656177A (en) * 1982-07-22 1987-04-07 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5443838A (en) * 1993-09-15 1995-08-22 Koenig, Jr.; Steven M. Nutritional supplementation system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717624A1 (en) 1993-09-07 1996-06-26 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
DK0888286T3 (da) * 1996-03-14 2002-02-18 Warner Lambert Co Nye substituerede cykliske aminosyrer som farmaceutiske midler
DE69733081T2 (de) 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
NZ334898A (en) 1996-10-23 2000-09-29 Warner Lambert Co Substituted gamma aminobutyric acids as pharamceutical agents
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656177A (en) * 1982-07-22 1987-04-07 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5443838A (en) * 1993-09-15 1995-08-22 Koenig, Jr.; Steven M. Nutritional supplementation system

Also Published As

Publication number Publication date
BR9911917A (pt) 2001-03-27
WO2000002562A1 (en) 2000-01-20
CA2332915A1 (en) 2000-01-20
ID28277A (id) 2001-05-10
NZ508490A (en) 2003-08-29
NO20010119L (no) 2001-01-08
ZA200007168B (en) 2002-03-04
JP2002520286A (ja) 2002-07-09
EP1094817A1 (en) 2001-05-02
US6326374B1 (en) 2001-12-04
KR20010071777A (ko) 2001-07-31
PL345340A1 (en) 2001-12-17
NO20010119D0 (no) 2001-01-08
AU4691099A (en) 2000-02-01
CA2332915C (en) 2006-10-24

Similar Documents

Publication Publication Date Title
US6326374B1 (en) Compositions comprising GABA analogs and caffeine
AU765038B2 (en) Method for the treatment of insomnia
EP0124091B1 (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
US6680343B1 (en) Treatment of renal colic with GABA analogs
AU765246B2 (en) Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles
US20040002543A1 (en) Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
AU758103B2 (en) Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
MXPA00011648A (es) Composiciones que comprenden analogos gaba y cafeina
CA2332931C (en) The treatment of renal colic with gaba analogs
AU3492900A (en) Combinations of gaba analogs and tricyclic compounds to treat depression
US20030045500A1 (en) Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
MXPA00011647A (en) The treatment of renal colic with gaba analogs
MXPA00011509A (en) Method for the treatment of insomnia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)